Oligodendroglioma Pipeline Review, H2 2018 - ResearchAndMarkets.com

October 12, 2018

DUBLIN--(BUSINESS WIRE)--Oct 12, 2018--The “Oligodendroglioma - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Oligodendroglioma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 9, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Oligodendroglioma - Overview Oligodendroglioma - Therapeutics Development Oligodendroglioma - Therapeutics Assessment Oligodendroglioma - Companies Involved in Therapeutics Development Oligodendroglioma - Drug Profiles Oligodendroglioma - Dormant Projects Oligodendroglioma - Discontinued Products Appendix

Companies Mentioned

AbbVie Inc AlfaSigma SpA AngioChem Inc Astellas Pharma Inc Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Co Eli Lilly and Co GtreeBNT Co Ltd Immatics Biotechnologies GmbH Ipsen SA Northwest Biotherapeutics Inc Novartis AG Pfizer Inc Taiho Pharmaceutical Co Ltd TheraBiologics Inc Tocagen Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vtsn55/oligodendroglioma?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181012005104/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Brain Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/12/2018 04:37 AM/DISC: 10/12/2018 04:37 AM


Update hourly